Exelixis Management
Management criteria checks 3/4
Exelixis' CEO is Mike Morrissey, appointed in Jul 2010, has a tenure of 13.92 years. total yearly compensation is $16.42M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $35.78M. The average tenure of the management team and the board of directors is 8.8 years and 7 years respectively.
Key information
Mike Morrissey
Chief executive officer
US$16.4m
Total compensation
| CEO salary percentage | 7.3% |
| CEO tenure | 13.9yrs |
| CEO ownership | 0.5% |
| Management average tenure | 8.8yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity
Jun 14
It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year
May 24Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality
May 07Exelixis: With Patent Litigation Decision Due Soon, There Are Options
May 02Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued
May 30Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise
Oct 18Exelixis: Efforts Continue To Diversify The Pipeline
Sep 15Exelixis, Teva fight over Cabometyx generic again
Sep 06Exelixis Needs To Move Away From Its Overdependence On Cabozantinib
Aug 03Exelixis again sues MSN Pharmaceuticals over Cabometyx generic
Jul 19Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs
Jul 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | n/a | n/a | US$208m |
| Sep 30 2023 | n/a | n/a | US$92m |
| Jun 30 2023 | n/a | n/a | US$164m |
| Mar 31 2023 | n/a | n/a | US$154m |
| Dec 31 2022 | US$17m | US$1m | US$182m |
| Sep 30 2022 | n/a | n/a | US$308m |
| Jun 30 2022 | n/a | n/a | US$273m |
| Mar 31 2022 | n/a | n/a | US$298m |
| Dec 31 2021 | US$8m | US$1m | US$231m |
| Sep 30 2021 | n/a | n/a | US$164m |
| Jun 30 2021 | n/a | n/a | US$94m |
| Mar 31 2021 | n/a | n/a | US$65m |
| Dec 31 2020 | n/a | n/a | US$112m |
| Sep 30 2020 | n/a | n/a | US$152m |
| Jun 30 2020 | n/a | n/a | US$282m |
| Mar 31 2020 | n/a | n/a | US$294m |
| Dec 31 2019 | n/a | n/a | US$321m |
| Sep 30 2019 | n/a | n/a | US$612m |
| Jun 30 2019 | n/a | n/a | US$642m |
| Mar 31 2019 | n/a | n/a | US$650m |
| Dec 31 2018 | n/a | n/a | US$690m |
| Sep 30 2018 | n/a | n/a | US$368m |
| Jun 30 2018 | n/a | n/a | US$323m |
| Mar 31 2018 | n/a | n/a | US$253m |
| Dec 31 2017 | n/a | n/a | US$154m |
Compensation vs Market: Mike's total compensation ($USD16.42M) is above average for companies of similar size in the US market ($USD8.45M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
CEO
Mike Morrissey (63 yo)
13.9yrs
Tenure
US$16,423,307
Compensation
Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chair of the Board | 29.5yrs | US$519.97k | 0.43% $ 27.9m | |
| CEO, President & Director | 13.9yrs | US$16.42m | 0.55% $ 35.8m | |
| Executive VP & CFO | 8.9yrs | US$4.95m | 0.16% $ 10.2m | |
| Executive VP of Discovery and Translational Research & Chief Scientific Officer | 1.5yrs | US$5.65m | 0.082% $ 5.4m | |
| Executive VP | 10.3yrs | US$4.56m | 0.12% $ 7.8m | |
| Executive VP | less than a year | US$7.38m | no data | |
| Executive Vice President of Public Affairs & Investor Relations | 7.5yrs | no data | no data | |
| Executive Vice President of Human Resources | 9.6yrs | no data | no data | |
| Senior Vice President of Drug Safety | 9.2yrs | no data | no data | |
| Senior Vice President of Medical Affairs | 8.8yrs | no data | no data | |
| Executive Vice President of Commercial | 7.5yrs | US$4.65m | 0.051% $ 3.4m | |
| VP & Head of Business Development | no data | no data | no data |
8.8yrs
Average Tenure
57yo
Average Age
Experienced Management: EXEL's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chair of the Board | 29.5yrs | US$519.97k | 0.43% $ 27.9m | |
| CEO, President & Director | 13.9yrs | US$16.42m | 0.55% $ 35.8m | |
| Independent Director | 20.3yrs | US$490.97k | 0.11% $ 7.5m | |
| Independent Director | 19.8yrs | US$482.22k | 0.066% $ 4.4m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 7.8yrs | US$490.92k | 0.0019% $ 122.7k | |
| Independent Director | 6.2yrs | US$488.72k | 0.021% $ 1.3m | |
| Independent Director | 1.1yrs | US$717.44k | 0.0016% $ 102.4k | |
| Independent Director | 1.1yrs | US$716.19k | 0.0016% $ 102.4k |
7.0yrs
Average Tenure
68yo
Average Age
Experienced Board: EXEL's board of directors are considered experienced (7 years average tenure).